These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25193038)

  • 1. Efficacy and safety of meropenem (3 g daily) in Japanese patients with refractory respiratory infections.
    Kawanami T; Mukae H; Noguchi S; Yamasaki K; Akata K; Ishimoto H; Matsumoto K; Morita K; Yatera K
    J Infect Chemother; 2014 Dec; 20(12):768-73. PubMed ID: 25193038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a pharmacokineticpharmacodynamic approach using software to optimize the carbapenem antibiotic regimen.
    Ishihara N; Nishimura N; Tamaki H; Karino F; Miura K; Isobe T; Ikawa K; Morikawa N; Naora K
    Int J Clin Pharmacol Ther; 2015 Jun; 53(6):422-9. PubMed ID: 25828635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.
    Oshima K; Nakamura S; Iwanaga N; Takemoto K; Miyazaki T; Yanagihara K; Miyazaki Y; Mukae H; Kohno S; Izumikawa K
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of high-dose doripenem in Japanese patients with pneumonia.
    Yatera K; Naito K; Noguchi S; Akata K; Yamasaki K; Nishida C; Kawanami T; Sakamoto N; Kido T; Ishimoto H; Mukae H
    J Infect Chemother; 2016 Mar; 22(3):137-42. PubMed ID: 26778252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan.
    Yamamoto Y; Izumikawa K; Morinaga Y; Nakamura S; Kurihara S; Imamura Y; Miyazaki T; Tsukamoto M; Kakeya H; Yanagihara K; Yasuoka A; Kohno S
    J Infect Chemother; 2013 Apr; 19(2):291-8. PubMed ID: 23345050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan.
    Morita A; Kamei S; Minami M; Yoshida K; Kawabata S; Kuroda H; Suzuki Y; Araki N; Iwasaki Y; Kobayashi R; Hayashi N; Hirayama T; Ochiai J; Ueda M; Yamagishi Y; Niwa J; Shindo K; Fukushima Y; Takita T; Sato T; Sato S; Mikamo H; Iwata S
    J Infect Chemother; 2014 Sep; 20(9):535-40. PubMed ID: 24882451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A phase III study of the efficacy and safety of meropenem in patients with febrile neutropenia].
    Imajo K; Ueda Y; Kawano F; Sao H; Kamimura T; Ito Y; Mugitani A; Suzuki K; Uike N; Miyamura K; Uski K; Morimatsu Y; Akiyama N; Nagai H; Ohara A; Tanimoto M; Takaki K; Chayama K; Urabe M; Nagatoshi Y; Tamura K
    Jpn J Antibiot; 2012 Aug; 65(4):271-87. PubMed ID: 23259257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients.
    Wen ZP; Fan SS; Du C; Yin T; Zhou BT; Peng ZF; Xie YY; Zhang W; Chen Y; Xiao J; Chen XP
    J Clin Pharm Ther; 2017 Apr; 42(2):221-227. PubMed ID: 28145574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies of meropenem in pediatric infections].
    Niinou K; Sato H; Nakazawa S
    Jpn J Antibiot; 1992 Jul; 45(7):833-44. PubMed ID: 1522675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa.
    Harashima S; Kondo H; Nabeshima A; Shimoda M; Yamaji K; Horiuchi T; Shimono N; Ikematsu H
    J Infect Chemother; 2008 Jun; 14(3):219-22. PubMed ID: 18574658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.
    Fujita M; Matsumoto T; Inoue Y; Wataya H; Takayama K; Ishida M; Ebi N; Kishimoto J; Ichinose Y;
    J Infect Chemother; 2016 Apr; 22(4):235-9. PubMed ID: 26867793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and pharmacokinetic evaluations of meropenem in children].
    Satoh K; Watanabe A
    Jpn J Antibiot; 1992 Jul; 45(7):814-20. PubMed ID: 1522672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital.
    Patel GW; Duquaine SM; McKinnon PS
    Pharmacotherapy; 2007 Dec; 27(12):1637-43. PubMed ID: 18041884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical monotherapy with meropenem in serious bacterial infections in children.
    Hsu HL; Lu CY; Tseng HY; Lee PI; Lai HP; Lin WC; Hsieh YC; Lee CY; Huang LM
    J Microbiol Immunol Infect; 2001 Dec; 34(4):275-80. PubMed ID: 11825008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.
    Frippiat F; Musuamba FT; Seidel L; Albert A; Denooz R; Charlier C; Van Bambeke F; Wallemacq P; Descy J; Lambermont B; Layios N; Damas P; Moutschen M
    J Antimicrob Chemother; 2015 Jan; 70(1):207-16. PubMed ID: 25216821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Laboratory and clinical evaluation of meropenem in pediatric field].
    Iwai N; Nakamura H; Miyazu M; Watanabe Y; Taneda Y
    Jpn J Antibiot; 1992 Oct; 45(10):1403-19. PubMed ID: 1479689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly.
    Namkoong H; Kameyama Y; Yasuda H; Nakayama S; Kaneko H; Kawashima C; Terajima T; Maezawa K; Hayashi T; Sandoh M; Ishii M; Tasaka S; Kanayama A; Kobayashi I; Betsuyaku T; Kizu J; Iwata S; Sato Y; Hasegawa N
    J Infect Chemother; 2014 Jun; 20(6):356-60. PubMed ID: 24725621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A; Meli EZ; Mazzocchi P; Speranza V
    Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.